share_log

康辰药业(603590.SH):KC1036联合PD-1抗体一线维持治疗局部晚期或转移性食管鳞癌获得临床试验通知书

Kangchen Pharmaceutical (603590.SH): KC1036 combined with PD-1 antibody first-line maintenance treatment for locally advanced or metastatic esophageal squamous cell carcinoma obtained a clinical trial notice

Gelonghui Finance ·  Dec 26, 2023 04:42

Gelonghui December 26丨Kangchen Pharmaceutical (603590.SH) announced that the company has received the “Clinical Trial Notice” of “KC1036 with PD-1 Antibody First-Line Maintenance Treatment for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma” approved and issued by the State Drug Administration. KC1036 is a Class 1 innovative chemical drug independently developed by the company, and the company has global intellectual property rights for this product. KC1036 achieves anti-tumor activity by inhibiting multiple targets such as VEGFR2 and AXL. KC1036 has a strong VEGFR vascular target and inhibits tumor cell growth; by inhibiting AXL, the host's anti-tumor immune response can be improved, thereby avoiding tumor immune escape.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment